Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Gains from Investment Securities (2021 - 2025)

SAB Biotherapeutics' Gains from Investment Securities history spans 5 years, with the latest figure at $32484.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 626.4% year-over-year to $32484.0; the TTM value through Dec 2025 reached $3.7 million, down 84.27%, while the annual FY2025 figure was $20.9 million, 603.78% up from the prior year.
  • Gains from Investment Securities reached $32484.0 in Q3 2025 per SABSW's latest filing, down from $627056.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $10.4 million in Q4 2022 to a low of -$7.8 million in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $1.5 million, with a median of $499699.0 recorded in 2021.
  • The largest YoY upside for Gains from Investment Securities was 1986.8% in 2022 against a maximum downside of 17362.81% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $499699.0 in 2021, then skyrocketed by 1986.8% to $10.4 million in 2022, then plummeted by 54.67% to $4.7 million in 2023, then surged by 70.5% to $8.1 million in 2024, then tumbled by 99.6% to $32484.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Gains from Investment Securities are $32484.0 (Q3 2025), $627056.0 (Q2 2025), and -$5.0 million (Q1 2025).